Company Description
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases.
The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines.
Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.
The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
| Country | United States |
| Founded | 1982 |
| IPO Date | Mar 5, 1985 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Stacy Lindborg |
Contact Details
Address: 997 Lenox Drive, Suite 100 Lawrenceville, New Jersey 08648 United States | |
| Phone | 609 896 9100 |
| Website | imunon.com |
Stock Details
| Ticker Symbol | IMNN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000749647 |
| ISIN Number | US15117N6022 |
| Employer ID | 52-1256615 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stacy R. Lindborg Ph.D. | President, Chief Executive Officer and Director |
| Michael H. Tardugno | Executive Chairman |
| Dr. Khursheed Anwer M.B.A., Ph.D. | Executive Vice President and Chief Scientific Officer |
| Timothy J. Tumminello CPA | Chief Accounting Officer and Controller |
| Susan Mary Eylward | General Counsel and Corporate Secretary |
| Dr. Sebastien Hazard M.D. | Executive Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Oct 7, 2024 | 8-K | Current Report |
| Sep 27, 2024 | 424B3 | Prospectus |
| Sep 26, 2024 | EFFECT | Notice of Effectiveness |
| Sep 20, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 5, 2024 | UPLOAD | Filing |
| Sep 3, 2024 | 8-K | Current Report |